Idelalisib Completed Phase 2 Trials for Lymphoplasmacytic Lymphoma / Follicular Lymphoma (FL) / Small Lymphocytic Lymphoma (SLL) / Marginal Zone Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01282424Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas